The pro-oncogenic adaptor CIN85 acts as an inhibitory binding partner of hypoxia-inducible factor prolyl hydroxylase 2

The EGFR-adaptor protein CIN85 has been shown to promote breast cancer malignancy and hypoxia-inducible factor(HIF) stability. However, the mechanisms underlying cancer promotion remain ill-defined. Here we show that CIN85 is a novel binding partner of the main HIF-prolyl hydroxylase PHD2, but not of PHD1 or PHD3. Mechanistically, the N-terminal SH3 domainsof CIN85 interacted with the proline-arginine rich region within the N-terminusof PHD2, thereby inhibiting PHD2 activity and HIF-degradation. This activity is essential in vivo, as specific loss of the CIN85-PHD2 interaction in CRISPR/ Cas9edited cells affected growth and migration properties as well as tumor growth in mice. Overall, we discovered a previously unrecognized tumor growth checkpoint that is regulated by CIN85-PHD2 and uncovered an essential survival functionin tumor cells by linking growth factor adaptors with hypoxia signaling.